 |
Amersham is a world leader in medical diagnostics and in life sciences.
We employ 9,500 people around the world. Our shares are traded on
the London, New York and Oslo stock exchanges (AHM), and we are
listed on the FTSE Index of Britain’s 100 largest companies.
Our company was formed in 1997 from the businesses of Amersham
International (UK), Pharmacia Biotech (Sweden) and Nycomed (Norway).
In 2001 the company changed its name to Amersham plc and our businesses
became Amersham Biosciences and Amersham Health. Together we combine
skills in understanding genetic predisposition and the molecular
basis of disease, with those for screening for disease.
Amersham Biosciences develops integrated systems and solutions
used for research into genes and proteins and their role in the
causes of disease; drug discovery; and the development and manufacture
of pharmaceuticals.
Amersham Health provides pharmaceuticals used for early, accurate
diagnosis of heart disease, circulatory disorders, lung disease,
diseases of the brain and cancer. It also provides radiotherapy
products for the treatment of cancer.
We have a long-standing commitment to research and development
and a strong track record of innovation. In 2001 we invested over
£170 million in R&D.
|
